Form 4: Acrivon Therapeutics COO Eric Devroe Reports Share Disposal for Tax Obligations

Eric Devroe, COO of Acrivon Therapeutics, disposed of 613 shares to cover tax obligations related to vesting restricted stock units.

Summary

• On May 14, 2025, Eric Devroe, the Chief Operating Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction involving the disposal of 613 shares of common stock.
• The shares were disposed of to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• The transaction was executed at a price of $1.14 per share.
• Following the transaction, Devroe directly owns 66,534 shares of Acrivon Therapeutics.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to tax obligations, which is neither particularly positive nor negative. It's a neutral event in terms of investment sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment with company performance.

Comparison to Industry Standards

• Similar transactions are common among executives receiving stock-based compensation, as they often need to sell shares to cover tax liabilities upon vesting.
• The number of shares sold is relatively small compared to the total shares owned, suggesting it's a routine tax-related transaction.

Stakeholder Impact

• The transaction has a minimal impact on shareholders, as it involves a small number of shares and is related to tax obligations.

Key Dates

Keywords

Form 4, Acrivon Therapeutics, Eric Devroe, ACRV, Share Disposal, Tax Withholding, Restricted Stock Units, Beneficial Ownership, Officer Transaction